Business Context and Reporting Period
Company: TriSalus Life Sciences, Inc. (TLSI)
Filing Type: Form 8-K (Current Report)
Date of Report: January 23, 2025
Reporting Period: Preliminary unaudited financial results for the year and quarter ended December 31, 2024.
Context: The Company is an emerging growth company incorporated in Delaware. This filing announces preliminary results via a press release (Exhibit 99.1) but explicitly states that the financial information is furnished and not "filed" for purposes of Section 18 of the Exchange Act.
Key Financial Metrics
The provided text serves as a cover document referencing a press release for specific data. Consequently, the filing text does not provide clear values for the following metrics:
- Revenue: Not stated in the text.
- Profit/Loss: Not stated in the text.
- Cash Flow: Not stated in the text.
- Margins: Not stated in the text.
- Debt and Liquidity: Not stated in the text.
Material Changes
The filing text does not contain specific comparative data or descriptions of material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
Guidance and Outlook: The text does not contain specific forward-looking guidance or management commentary regarding future performance.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt, other than the standard legal disclaimer that the furnished information is not subject to the liabilities of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated January 23, 2025) for the actual numerical values of revenue, net income, and cash position.
- Verify the status of the Company's Warrants (TLSIW) with an exercise price of $11.50 per share listed on the Nasdaq Global Market.
- Confirm the unaudited nature of the preliminary results and check for any subsequent updates or restatements in future filings.
- Assess the implications of the Company's designation as an emerging growth company on financial reporting standards.